Artivion (NYSE:AORT) Posts Earnings Results, Misses Estimates By $0.51 EPS

Artivion (NYSE:AORT) announced its earnings results on Monday. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51), reports. The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Artivion updated its FY 2025 guidance to EPS.

Artivion Price Performance

Shares of AORT stock traded down $3.18 during mid-day trading on Tuesday, hitting $24.67. The company had a trading volume of 308,739 shares, compared to its average volume of 345,569. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock’s 50 day moving average price is $29.75 and its 200-day moving average price is $27.83. Artivion has a 52-week low of $18.38 and a 52-week high of $32.33. The company has a market capitalization of $1.03 billion, a P/E ratio of -1,223.50 and a beta of 1.75.

Insiders Place Their Bets

In other Artivion news, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now directly owns 33,503 shares of the company’s stock, valued at $1,005,090. This trade represents a 18.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the completion of the transaction, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock worth $600,007 in the last 90 days. 8.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of recent analyst reports. Stifel Nicolaus cut their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Oppenheimer raised their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Finally, Needham & Company LLC dropped their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.